Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Gynecological Cancer × anlotinib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 34 Small Cell Lung Carcinoma 15 Breast Neoplasms 12 Sarcoma 10 Lung Neoplasms 9 Thyroid Neoplasms 6 Stomach Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 NSCLC 5 Carcinoma, Hepatocellular 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Esophageal Neoplasms 4 Carcinoma 4 Neoplasms 3 Nasopharyngeal Carcinoma 3 Glioma 3 Colorectal Neoplasms 3 Cholangiocarcinoma 3 Brain Neoplasms 3 Biliary Tract Neoplasms 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Triple Negative Breast Neoplasms 2 Recurrence 2 Platinum-resistant Ovarian Cancer 2 Pheochromocytoma 2 Paraganglioma 2 Ovarian Diseases 2 Non-squamous Non-small Cell Lung Cancer 2

Interventions

penpulimab 1 anlotinib 1 Laparoscopy 1 Injections, Spinal 1 Injections, Epidural 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05028504 2023-12-27

ALTER-GO-020

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown

Gynecological Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡